Global
and China Insulin Market (Rapid-Acting, Short-Acting,
Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin)
- Industry Analysis, Size, Share, Growth, Trends and Forecast (Value
and Volume), 2013 - 2019", the global insulin market was valued
at USD 19.99 billion in 2012 and is expected to grow at a CAGR of
6.1% from 2013 to 2019 to reach USD 32.24 billion in 2019.
Browse
the full Global and China Insulin Market Report with TOC at
http://www.transparencymarketresearch.com/insulin-market.html
Rising
prevalence of diabetes is one of the serious healthcare concerns on a
global level. Insulin is a hormone secreted by pancreas to absorb the
blood sugar. However, in diabetes, it is either not possible for the
body to secrete insulin (type-1) or to utilize secreted insulin to
metabolize glucose (type-2). Insulin deficiency in diabetic patients
is the most important factor driving the insulin market globally.
Rising prevalence of diabetes and extensive R&D activities are
the other key factors boosting growth in the insulin market. No
permanent cure has been invented for diabetes, thus the evolution of
insulin therapy has emerged as an indispensible treatment therapy for
type-1 diabetes patients.
The
global and China insulin market is segmented based on source and mode
of action. The insulin market by source is categorized as modern
insulin and human insulin. The modern insulin segment is expected to
grow at the fastest rate during the forecast period from 2013 to
2019, globally as well as in China. The insulin market by mode of
action is segmented into rapid-acting, short-acting,
intermediate-acting, long-acting and premixed insulin derivatives.
Due to advantages over other derivatives, the long-acting derivatives
segment is expected to grow rapidly during the forecast period.
Browse
Press Release of Global and China Insulin Market at @
http://www.transparencymarketresearch.com/pressrelease/insulin-market.htm
The
segment held the largest share of 42.77% of the total market in 2012.
It is expected to be the largest segment by the end of 2019.
Rapid-acting insulin was the second largest segment in 2012. Other
segments such as premixed, intermediate-acting and short-acting
insulin derivatives are expected to lose market share during the
forecast period. This is mainly due to low patient preference and
lack of R&D in these segments. Pharmaceutical companies have
concentrated their R&D strategies towards long-acting and
rapid-acting derivatives development, which would boost market
growth.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=259
The
rapid-acting, long-acting and premixed derivatives segments are the
most important segments in China. Growth in these segments is mainly
attributed to rising population of type-1 diabetes and growing
tendency of type-2 diabetes patients to use insulin as a therapeutic
agent.
The
insulin market in China is expected to grow steadily due to extensive
R&D activities for the development of new insulin analogs and
formulations that can be administered via different routes. Various
products such as LY2605541 (Eli Lilly and Company), MK-1293 (Merck &
Co., Inc.), NN1218 (Novo Nordisk A/S) and Afrezza (MannKind
Corporation) are under pipeline studies and are expected to enter the
market during the forecast period. Due to these new formulations, the
market is likely to grow steadily during the forecast period.
Browse
All Market Research Press Releases at:
http://www.transparencymarketresearch.com/press-releases.htm
The
insulin market is highly consolidated and dominated by select players
operating on a global level such as Novo Nordisk A/S, Eli Lilly and
Company, and Sanofi. In China, local and regional players such as
Shanghai Fosun Pharmaceuticals Pvt. Ltd. and Tonghua Dongbao also
contribute to the insulin market.
Browse
all Article :
http://www.transparencymarketresearch.com/articles.htm
The
global and China insulin market is segmented as follows:
Global
and China Insulin Market, by Mode of Action
Rapid-Acting
Short-Acting
Intermediate-Acting
Premixed
Long-Acting
Global
and China Insulin Market, by Source
Modern
Insulin
Human
Insulin
Browse
All Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research (TMR) is a market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. TMR's
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Ms.
Sheela AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Company
Blog: http://www.tmrblog.com/
Blog:
http://transparencymarketresearch.areavoices.com/
No comments:
Post a Comment